## Acid Suppression Raises Hip Fracture Risk

BY ANN C. LOGUE Contributing Writer

CHICAGO — Long-term use of protonpump inhibitors, histamine<sub>2</sub>-receptor antagonists, and other acid suppressors increases the risk of hip fracture, Yu-Xiao Yang, M.D., reported at the annual Digestive Disease Week.

Physicians turning to a combination of NSAIDs and proton-pump inhibitors (PPIs) in place of cyclooxygenase-2 (COX-2) inhibitors should be aware of this effect in patients who are at increased risk of osteoporosis, but they should not deny this therapy to patients with appropriate indications, said Dr. Yang of the di-

	rang of the di-
The relative risk	vision of gas-
	troenterology
of hip fracture	at the Universi-
associated with	ty of Pennsyl-
associated with	vania, Philadel-
PPI use was	phia.
much higher	PPIs interfere
-	with calcium
among men than	absorption,
among women.	leading to an in-
	creased risk of
	hip fracture.
<b>(() ) ) ) ) )</b>	1

"Do patients with more than 1 year of PPI therapy have more hip fractures? Up until now, there has been no epidemiological study to address this," Dr. Yang said.

His conclusions came from a retrospective cohort study of 518,096 patients older than 40 years who were included in the U.K. General Practice Research Database between May 1987 and April 2002. Of these, 47,631 had more than 1 year of exposure to a PPI; the remaining 470,465 patients had no exposure to either a PPI or histamine<sub>2</sub>-receptor antagonist (H2RA).

By looking at complete prescription information and validated hip fracture reports, the researchers discovered that taking a PPI long term was associated with an increased risk of hip fracture, with a relative risk of 1.9 associated with at least 1 year of PPI use. The relationship had both a dose-response effect and a duration-response effect. H2RA use also increased the relative risk of hip fracture, but to a lesser extent.


In general, the PPI-exposed patients



You have FREE access to articles from this issue and past issues of Family Practice News at www.familypracticenews.com were sicker and took more medications, so potential confounders were considered and adjusted for if they represented markers of comorbidity status or if they had an effect on the central nervous system that would increase the risk of falling, Dr. Yang said. After adjustment for potential confounders, there was still a significantly increased risk of hip fracture among long-term PPI users. Significant confounders included antidepressant use and an increased number of office visits.

Another hypothesis of the study, Dr. Yang said, is that men would be at greater risk because they do not take calcium supplements and do not talk about osteoporosis with their doctors. And, in fact, the data show just that: The relative risk of hip fracture associated with PPI use was much higher among men than among women.

The study was limited by the assumption of 100% compliance with therapy and the lack of information on use of over-thecounter drugs, Dr. Yang said.





\*Zolpidem tartrate worldwide.

## AMBIEN is the #1 prescribed sleep agent in the US<sup>2</sup>

AMBIEN is indicated for the short-term treatment of insomnia. In elderly or debilitated patients, or patients with hepatic dysfunction, treatment should be initiated with a 5-mg dose and patients closely monitored. Due to its rapid onset of action, patients which heptite dystancion, dedining before going to bed and when ready for sleep. Patients should not take AMBIEN unless they are prepared to get a full night's sleep (7 to 8 hours) to avoid residual effects. Until they know how it will affect their physical or mental performance upon awakening, patients should not drive or operate hazardous machinery after taking AMBIEN or any other sleep medication. During short-term treatment with AMBIEN, the most commonly observed adverse effects in controlled clinical trials were drowsiness (2%), dizziness (1%), and diarrhea (1%). Because individuals with a history of addiction or substance abuse are at increased risk of habituation and dependence, they should be under careful surveillance when receiving AMBIEN or any other hypnotic. AMBIEN is classified as a Schedule IV controlled substance. Sedative hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. Hypnotics should generally be limited to 7 to 10 days of use, and reevaluation of the patient is recommended if they

are taken for more than 2 to 3 weeks. Prescriptions for AMBIEN should not exceed a 1-month supply.

Please see brief summary of prescribing information on back.

## sanofi aventis

Sanofi-Synthelabo Inc., a member of the sanofi-aventis Group ©2005 Sanofi-Synthelabo Inc. 57-050003

